BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 26758663)

  • 1. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
    Nagashima S; Bao Y; Hata Y
    Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ.
    Kodaka M; Hata Y
    Cell Mol Life Sci; 2015 Jan; 72(2):285-306. PubMed ID: 25266986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of Hippo pathway in gastric and other gastrointestinal cancers.
    Kang W; Cheng AS; Yu J; To KF
    World J Gastroenterol; 2016 Jan; 22(3):1279-88. PubMed ID: 26811664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
    Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.
    Kim MH; Kim J
    Cell Mol Life Sci; 2017 Apr; 74(8):1457-1474. PubMed ID: 27826640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice.
    Nishio M; Sugimachi K; Goto H; Wang J; Morikawa T; Miyachi Y; Takano Y; Hikasa H; Itoh T; Suzuki SO; Kurihara H; Aishima S; Leask A; Sasaki T; Nakano T; Nishina H; Nishikawa Y; Sekido Y; Nakao K; Shin-Ya K; Mimori K; Suzuki A
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E71-80. PubMed ID: 26699479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hippo Pathway in Prostate Cancer.
    Salem O; Hansen CG
    Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of
    Goto H; Nishio M; To Y; Oishi T; Miyachi Y; Maehama T; Nishina H; Akiyama H; Mak TW; Makii Y; Saito T; Yasoda A; Tsumaki N; Suzuki A
    Development; 2018 Mar; 145(6):. PubMed ID: 29511023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
    Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
    J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP/TAZ at the Roots of Cancer.
    Zanconato F; Cordenonsi M; Piccolo S
    Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hippo Signaling Pathway in Pancreatic Cancer.
    Ansari D; Ohlsson H; Althini C; Bauden M; Zhou Q; Hu D; Andersson R
    Anticancer Res; 2019 Jul; 39(7):3317-3321. PubMed ID: 31262852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel YAP1 Activator, Identified by Transcription-Based Functional Screen, Limits Multiple Myeloma Growth.
    Maruyama J; Inami K; Michishita F; Jiang X; Iwasa H; Nakagawa K; Ishigami-Yuasa M; Kagechika H; Miyamura N; Hirayama J; Nishina H; Nogawa D; Yamamoto K; Hata Y
    Mol Cancer Res; 2018 Feb; 16(2):197-211. PubMed ID: 29061667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis.
    Patel SH; Camargo FD; Yimlamai D
    Gastroenterology; 2017 Feb; 152(3):533-545. PubMed ID: 28003097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxic conditions differentially regulate TAZ and YAP in cancer cells.
    Yan L; Cai Q; Xu Y
    Arch Biochem Biophys; 2014 Nov; 562():31-6. PubMed ID: 25078107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer.
    Li Z; Wang Y; Zhu Y; Yuan C; Wang D; Zhang W; Qi B; Qiu J; Song X; Ye J; Wu H; Jiang H; Liu L; Zhang Y; Song LN; Yang J; Cheng J
    Mol Oncol; 2015 Jun; 9(6):1091-105. PubMed ID: 25704916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
    Rozengurt E; Eibl G
    World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.